Cheng Andrew, President and CEO of Akero Therapeutics (AKRO), has demonstrated a clear selling bias in recent insider transactions, with $5.99 million in total sales outweighing $770,455 in purchases across 33 reported trades. The most significant disposals occurred on October 10, 2025, when Cheng sold shares worth $1.62 million alongside a $596,100 market purchase, followed by earlier September 2025 sales totaling $1.37 million across multiple transactions. Notably, all recent activity has been concentrated in AKRO, with no purchases recorded since October 2025 and five sales executed since September. The transactions include a mix of open market sales (code S) and market purchases (code M), with the most recent filings from November-December 2025 showing derivative transactions (codes D and G) with no reported value. This pattern suggests a net reduction in Cheng's AKRO position during the observed period, particularly through the liquidation of substantial holdings in late 2025. The absence of any disclosed purchases after October contrasts with the earlier activity that included both acquisitions and disposals.
AI-assisted summary